The Use of Fluoroscan in Hand Clinic During the Covid Pandemic to Optimise Conservative Treatment
dc.contributor.author | Ashwood, Neil | |
dc.date.accessioned | 2022-10-19T13:41:16Z | |
dc.date.available | 2022-10-19T13:41:16Z | |
dc.identifier.citation | Cureus 14(9): e29494 | en_US |
dc.identifier.uri | http://hdl.handle.net/20.500.12904/15846 | |
dc.description.abstract | Introduction The study assessed the use of Fluoroscan (Hologic, Inc., Marlborough, MA) in hand clinic as advised by the British Orthopaedic Association (BOA) during the COVID-19 pandemic to facilitate treatment of fractures requiring manipulation and reduce admissions to evaluate if this should be embedded in practice permanently. Method Eighty-three wrist and hand fractures requiring manipulation were identified between April 2020 and March 2021. Demographics, mechanism of injury, timing of intervention, radiological outcome, further intervention and functional assessment by QuickDASH scoring were recorded. Results Sixty-eight cases were manipulated within the first week of fracture, simple pain control measures were used, and dose area product (DAP) averaged 1.3 Gy cm2 well below the dose limit set by the trust. Satisfactory fracture reduction was achieved in 59 cases avoiding admission. Further surgical intervention was offered to 24 patients: five re-manipulated while 19 had operation, all with a good functional outcome. Conclusion Fluoroscan use in fracture clinics achieved effective fracture control in 77% of cases. The use of Fluoroscan avoided admissions for surgery during the pandemic and lengthy clinic visits, four out of five did not need admission. | |
dc.subject | Clinic | en_US |
dc.subject | Hand | en_US |
dc.subject | Pandemic | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Fluoroscan | en_US |
dc.title | The Use of Fluoroscan in Hand Clinic During the Covid Pandemic to Optimise Conservative Treatment | en_US |
dc.type | Article | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |
rioxxterms.version | NA | en_US |
rioxxterms.versionofrecord | DOI: 10.7759/cureus.2949 | en_US |
rioxxterms.type | Journal Article/Review | en_US |
refterms.dateFOA | 2022-10-19T13:41:17Z | |
refterms.panel | Unspecified | en_US |
refterms.dateFirstOnline | 2022-09 | |
html.description.abstract | Introduction The study assessed the use of Fluoroscan (Hologic, Inc., Marlborough, MA) in hand clinic as advised by the British Orthopaedic Association (BOA) during the COVID-19 pandemic to facilitate treatment of fractures requiring manipulation and reduce admissions to evaluate if this should be embedded in practice permanently. Method Eighty-three wrist and hand fractures requiring manipulation were identified between April 2020 and March 2021. Demographics, mechanism of injury, timing of intervention, radiological outcome, further intervention and functional assessment by QuickDASH scoring were recorded. Results Sixty-eight cases were manipulated within the first week of fracture, simple pain control measures were used, and dose area product (DAP) averaged 1.3 Gy cm2 well below the dose limit set by the trust. Satisfactory fracture reduction was achieved in 59 cases avoiding admission. Further surgical intervention was offered to 24 patients: five re-manipulated while 19 had operation, all with a good functional outcome. Conclusion Fluoroscan use in fracture clinics achieved effective fracture control in 77% of cases. The use of Fluoroscan avoided admissions for surgery during the pandemic and lengthy clinic visits, four out of five did not need admission. | en_US |
rioxxterms.funder.project | 94a427429a5bcfef7dd04c33360d80cd | en_US |